Document is current
Any future updates will be listed below
-
Authors
Grigorascu, Sonia https://orcid.org/0009-0007-1861-3955
Langbein, Thomas
Rauscher, Isabel
D’Alessandria, Calogero
Maurer, Tobias
Hekimsoy, Türkay
Weber, Wolfgang A
Eiber, Matthias
-
Funding
Funding for this research was provided by:
Technische Universität München
- License Information
-
More Information
Article History
Received: 8 June 2024
Accepted: 29 August 2024
First Online: 12 November 2024
Declarations
:
: The analysis was approved by the Ethics Committee of the Technical University Munich (permit 99–19 S), and is in accordance with the principles of the Declaration of Helsinki. The requirement to obtain informed consent was waived.
: Not applicable.
: ME reports fees from Blue Earth Diagnostics Ltd. (consultant, research funding), Novartis/AAA (consultant), Telix (consultant), Bayer (consultant, research funding), RayzeBio (consultant), Point Biopharma (consultant) and Janssen Pharmaceuticals (consultant, speakers bureau), Parexel (image review) and Bioclinica (image review) outside the submitted work and a patent application for rhPSMA. WW is on the advisory boards and receives compensation from Blue Earth Diagnostics, ITG and Pentixapharm. He has received research support from Blue Earth Diagnostics, BMS, and Pentixapharm. He is also an advisory editor for EJNMMI Research. IR is an associate editor for EJNMMI Research. No other potential conflicts of interest relevant to this article exist. The other authors, SG, TL, TH, CDA and TM, have no relevant financial or non-financial interests to disclose.
